Bristol-Myers Squibb Company (BMY)
BMY Q2 Earnings Call Highlights Growth Portfolio Momentum
BMY highlights growth portfolio momentum, raises 2026 outlook and advances pipeline priorities as newer medicines drive results.
Bristol-Myers Squibb Company (BMY) Q2 2026 Earnings Call Transcript
Bristol-Myers Squibb Company (BMY) Q2 2026 Earnings Call Transcript
BMY Q2 Earnings Beat Estimates, '26 View Raised, Stock Up
Bristol Myers??? tops Q2 earnings and revenue estimates, raises 2026 guidance, and sees strong momentum from its Growth Portfolio and higher Eliquis demand.
Bristol Myers Squibb: Upgrading To Buy On Positive Q2 Earnings, Long-Term Outlook
Bristol Myers Squibb delivered strong Q2 2026 results, with revenue and EPS both exceeding expectations and robust cash flow performance. BMY's forward P/E of ~9.2x and P/S of ~2.6x, combined with a ~4% dividend yield, suggest the stock is undervalued versus Big Pharma peers. While legacy portfolio revenues decline due to patent expiries, the growth portfolio is gaining traction, though some assets have underperformed expectations.
Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.46 per share a year ago.
Bristol Myers Lifts Outlook as Profit, Revenue Rise
Bristol Myers Squibb raised its outlook for the year after notching higher profit and revenue in the latest quarter, boosted by its portfolio of newer treatments.
Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
Bristol Myers Squibb raised its full-year revenue and profit forecast on Thursday after reporting second-quarter results that came in well ahead of Wall Street estimates, driven by strong sales of blood thinner Eliquis and newer drugs like heart medicine Camzyos and anemia treatment Reblozyl.
Bristol Myers Raises Earnings Guidance as Newer Drugs Drive Big Quarterly Beat
Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.
Wall Street's Insights Into Key Metrics Ahead of Bristol Myers (BMY) Q2 Earnings
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
